Ticker LaunchIPO · PASG
Passage BIO, Inc.
Passage BIO, Inc. (PASG) priced its initial public offering on Feb 28, 2020 at $18.00 per share, within its $16.00–$18.00 range, raising $216M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $792M. Fenwick & West advised the company and Cooley advised the underwriters.
Passage Bio, Inc. is a genetic medicines company developing therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. It has a strategic research collaboration to support its work in this area.
- Status
- IPO
- Ticker
- PASG
- Exchange
- Nasdaq Global Select
- Priced
- Feb 28, 2020
- IPO price
- $18.00
- Price range
- $16.00–$18.00
- Raised
- $216M
- Market cap at IPO price
- $792M
- First filed
- Feb 3, 2020
- Company counsel
- Fenwick & West
- Underwriters' counsel
- Cooley
- Sector
- Biotech & pharma
- Country / state
- PA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Feb 3, 2020
- Latest amendment Feb 27, 2020
- Final prospectus (424B4) Feb 28, 2020
- All filings on EDGAR CIK 1787297
Other Biotech & pharma IPOs in 2020
- Enliven Therapeutics, Inc.IMRA · Mar 12, 2020 · $75.2M
- Revolution Medicines, Inc.RVMD · Feb 13, 2020 · $238M
- Beam Therapeutics Inc.BEAM · Feb 7, 2020 · $180M
- PPD, Inc.PPD · Feb 6, 2020 · $1.62B
- Schrodinger, Inc.SDGR · Feb 6, 2020 · $202M
- Arcutis Biotherapeutics, Inc.ARQT · Jan 31, 2020 · $159.4M